ECSP18074962A - Derivados de aminotiazol útiles como agentes antivíricos - Google Patents

Derivados de aminotiazol útiles como agentes antivíricos

Info

Publication number
ECSP18074962A
ECSP18074962A ECSENADI201874962A ECDI201874962A ECSP18074962A EC SP18074962 A ECSP18074962 A EC SP18074962A EC SENADI201874962 A ECSENADI201874962 A EC SENADI201874962A EC DI201874962 A ECDI201874962 A EC DI201874962A EC SP18074962 A ECSP18074962 A EC SP18074962A
Authority
EC
Ecuador
Prior art keywords
antitiviral
aminotiazole
agents
derivatives useful
medicines
Prior art date
Application number
ECSENADI201874962A
Other languages
English (en)
Inventor
Gerald Kleymann
Christian Gege
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55701658&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP18074962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of ECSP18074962A publication Critical patent/ECSP18074962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

La invención se refiere a nuevos compuestos de la Fórmula (I), a un proceso para su preparación y a su uso como medicamentos, en particular como medicamentos antivíricos.
ECSENADI201874962A 2016-04-06 2018-10-04 Derivados de aminotiazol útiles como agentes antivíricos ECSP18074962A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16000787 2016-04-06

Publications (1)

Publication Number Publication Date
ECSP18074962A true ECSP18074962A (es) 2018-11-30

Family

ID=55701658

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201874962A ECSP18074962A (es) 2016-04-06 2018-10-04 Derivados de aminotiazol útiles como agentes antivíricos

Country Status (27)

Country Link
US (2) US10590094B2 (es)
EP (1) EP3440063B1 (es)
JP (1) JP6918823B2 (es)
KR (1) KR102354411B1 (es)
CN (1) CN109071473B (es)
AR (1) AR108175A1 (es)
AU (1) AU2017245679B2 (es)
BR (1) BR112018070448A2 (es)
CA (1) CA3018026A1 (es)
CL (1) CL2018002811A1 (es)
CO (1) CO2018010689A2 (es)
CR (1) CR20180482A (es)
CU (1) CU24519B1 (es)
EA (1) EA035401B1 (es)
EC (1) ECSP18074962A (es)
ES (1) ES2834051T3 (es)
GE (1) GEP20207128B (es)
IL (1) IL261421A (es)
MX (2) MX2018012116A (es)
MY (1) MY198018A (es)
PE (1) PE20181804A1 (es)
PH (1) PH12018501979A1 (es)
SV (1) SV2018005760A (es)
TW (1) TWI706940B (es)
UA (1) UA123734C2 (es)
UY (1) UY37193A (es)
WO (1) WO2017174640A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107118207B (zh) * 2017-05-22 2020-10-02 苏州东南药业股份有限公司 一类cdk抑制剂的制备方法
AR113344A1 (es) * 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CA3196645A1 (en) 2020-10-29 2022-05-05 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds
WO2023135303A1 (en) 2022-01-17 2023-07-20 Innovative Molecules Gmbh Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2024049760A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
DE69624728T2 (de) 1995-12-29 2003-07-10 Boehringer Ingelheim Pharma Phenyl thiazol derivate mit antiherpesvirus eigenschaften
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
DK1064273T3 (da) 1998-03-19 2003-03-31 Upjohn Co 1,3,4-Thiadiazoler, som er nyttige til behandling af CMV-infektioner
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
AU2914200A (en) 1999-03-08 2000-09-28 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
WO2001096874A1 (en) 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129715A1 (de) 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
JP4960708B2 (ja) 2004-01-30 2012-06-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
WO2012061190A1 (en) * 2010-11-01 2012-05-10 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
JP2019515883A (ja) 2019-06-13
SV2018005760A (es) 2019-03-08
MY198018A (en) 2023-07-26
CN109071473B (zh) 2022-12-09
MX2018012116A (es) 2019-05-23
PH12018501979A1 (en) 2019-07-01
EP3440063A1 (en) 2019-02-13
TWI706940B (zh) 2020-10-11
IL261421A (en) 2018-10-31
CL2018002811A1 (es) 2019-02-08
ES2834051T3 (es) 2021-06-16
TW201738217A (zh) 2017-11-01
CU20180124A7 (es) 2019-04-04
CO2018010689A2 (es) 2018-10-22
AU2017245679B2 (en) 2021-07-01
KR102354411B1 (ko) 2022-01-21
AR108175A1 (es) 2018-07-25
US10590094B2 (en) 2020-03-17
KR20180132674A (ko) 2018-12-12
CU24519B1 (es) 2021-06-08
UA123734C2 (uk) 2021-05-26
CN109071473A (zh) 2018-12-21
US20200148652A1 (en) 2020-05-14
US20190112285A1 (en) 2019-04-18
EA201892246A1 (ru) 2019-04-30
BR112018070448A2 (pt) 2019-02-05
GEP20207128B (en) 2020-07-10
UY37193A (es) 2017-11-30
PE20181804A1 (es) 2018-11-19
EP3440063B1 (en) 2020-08-05
JP6918823B2 (ja) 2021-08-11
MX2020005079A (es) 2020-08-13
CR20180482A (es) 2019-04-09
CA3018026A1 (en) 2017-10-12
WO2017174640A1 (en) 2017-10-12
AU2017245679A1 (en) 2018-10-04
EA035401B1 (ru) 2020-06-08

Similar Documents

Publication Publication Date Title
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170575A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen.
UY35467A (es) Compuestos orgánicos
UY35915A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36735A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
GT201500116A (es) Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo